| Literature DB >> 27445159 |
Megan S Lord1, Bill Cheng2, Fengying Tang2, J Guy Lyons3, Jelena Rnjak-Kovacina2, John M Whitelock2.
Abstract
Heparin is a carbohydrate anticoagulant used clinically to prevent thrombosis, however impurities can limit its efficacy. Here we report the biosynthesis of heparin-like heparan sulfate via the recombinant expression of human serglycin in human cells. The expressed serglycin was also decorated with chondroitin/dermatan sulfate chains and the relative abundance of these glycosaminoglycan chains changed under different concentrations of glucose in the culture medium. The recombinantly expressed serglycin produced with 25mM glucose present in the culture medium was found to possess anticoagulant activity one-seventh of that of porcine unfractionated heparin, demonstrating that bioengineered human heparin-like heparan sulfate may be a safe next-generation pharmaceutical heparin. CrownEntities:
Keywords: Glycosaminoglycan; Heparin; Proteoglycan; Recombinant expression; Serglycin
Mesh:
Substances:
Year: 2016 PMID: 27445159 DOI: 10.1016/j.ymben.2016.07.006
Source DB: PubMed Journal: Metab Eng ISSN: 1096-7176 Impact factor: 9.783